Trioleyl Pyridinium, a Cationic Transfection Agent for the Lipofection of Therapeutic Oligonucleotides into Mammalian Cells

dc.contributor.authorDelgado, Ana
dc.contributor.authorGriera Farres, Rosa
dc.contributor.authorLlor Brunés, Núria
dc.contributor.authorLópez-Aguilar, Ester
dc.contributor.authorBusquets i Viñas, Ma. Antonia
dc.contributor.authorNoé Mata, Verónica
dc.contributor.authorCiudad i Gómez, Carlos Julián
dc.date.accessioned2023-02-23T09:38:13Z
dc.date.available2023-02-23T09:38:13Z
dc.date.issued2023
dc.date.updated2023-02-23T09:38:13Z
dc.description.abstractBackground: One of the most significant limitations that therapeutic oligonucleotides present is the development of specific and efficient delivery vectors for the internalization of nucleic acids into cells. Therefore, there is a need for the development of new transfection agents that ensure a proper and efficient delivery into mammalian cells. Methods: We describe the synthesis of 1,3,5-tris[(4-oelyl-1-pyridinio)methyl]benzene tribromide (TROPY) and proceeded to the validation of its binding capacity toward oligonucleotides, the internalization of DNA into the cells, the effect on cell viability, apoptosis, and its capability to transfect plasmid DNA. Results: The synthesis and chemical characterization of TROPY, which can bind DNA and transfect oligonucleotides into mammalian cells through clathrin and caveolin-mediated endocytosis, are described. Using a PPRH against the antiapoptotic survivin gene as a model, we validated that the complex TROPY-PPRH decreased cell viability in human cancer cells, increased apoptosis, and reduced survivin mRNA and protein levels. TROPY was also able to stably transfect plasmid DNA, as demonstrated by the formation of viable colonies upon the transfection of a dhfr minigene into dhfr-negative cells and the subsequent metabolic selection. Conclusions: TROPY is an efficient transfecting agent that allows the delivery of therapeutic oligonucleotides, such as PPRHs and plasmid DNA, inside mammalian cells. Keywords: therapeutic oligonucleotide; PPRH; hairpin; delivery; transfection agent; mammalian cell; cancer; cell viability; apoptosis; stable transfection
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec729899
dc.identifier.issn1999-4923
dc.identifier.urihttps://hdl.handle.net/2445/194009
dc.language.isoeng
dc.publisherMDPI
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3390/pharmaceutics15020420
dc.relation.ispartofPharmaceutics, 2023
dc.relation.urihttps://doi.org/10.3390/pharmaceutics15020420
dc.rightscc-by (c) Delgado, Ana et al., 2023
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.sourceArticles publicats en revistes (Farmacologia, Toxicologia i Química Terapèutica)
dc.subject.classificationOligonucleòtids
dc.subject.classificationSíntesi orgànica
dc.subject.otherOligonucleotides
dc.subject.otherOrganic synthesis
dc.titleTrioleyl Pyridinium, a Cationic Transfection Agent for the Lipofection of Therapeutic Oligonucleotides into Mammalian Cells
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
729899.pdf
Mida:
3.5 MB
Format:
Adobe Portable Document Format